Compare Cassava Sciences Inc (FLNA) vs Honeywell Aerospace Inc. Common Stock (HONA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Honeywell Aerospace Inc. Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Honeywell Aerospace Inc. Common Stock trades at $155.9 (market cap $50.14B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 1396.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (323,246 versus 1,433,364). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Honeywell Aerospace Inc. Common Stock for 0 Days on average.
| FLNA | HONA | |
|---|---|---|
Market Cap | $35.91M | $50.14B |
Volume | 323,246 | 1,433,364 |
Sector | Health | Industrials |
52-Week High | $4.64 | $269.95 |
52-Week Low | $0.68 | $151.58 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $64.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →
